Axsome Therapeutics (AXSM) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TG Therapeutics (TGTX) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 49.2% versus a gain of 37.4%. Over five years, AXSM leads with a +319.8% price change compared with +60.1% for TGTX. Axsome Therapeutics is the larger company by market cap ($8.82 billion vs $8.48 billion), about 1.0 times the size, while TG Therapeutics is growing revenue faster (+87.3% vs +65.5%).
On valuation, TG Therapeutics trades at a lower forward P/E (20.4x vs 35.8x for Axsome Therapeutics). TG Therapeutics converts more of its revenue into profit, with a net margin of 72.6% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | TGTX |
|---|---|---|
| Share price | $168.35 | $55.37 |
| Market cap | $8.82B | $8.48B |
| 1-day change | -1.02% | +3.81% |
| YTD return | -7.82% | +78.93% |
| 1-year return | +37.41% | +49.20% |
| 5-year return | +319.83% | +60.13% |
| P/E ratio (TTM) | — | 19.43 |
| Forward P/E | 35.80 | 20.45 |
| EPS (TTM) | $-3.74 | $2.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $616.29M |
| Revenue growth (YoY) | +65.55% | +87.32% |
| Net income (latest FY) | $-183.17M | $447.18M |
| Gross margin | 92.56% | 83.66% |
| Operating margin | -26.12% | 20.01% |
| Net margin | -28.69% | 72.56% |
| 52-week high | $260.19 | $59.30 |
| 52-week low | $119.20 | $26.76 |
| Distance from 52-week high | -35.30% | -6.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +69.07% | +25.90% |
| Average volume | 710.84K | 2.01M |
| Shares outstanding | 52.38M | 153.08M |
| Employees | 1,346 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed AXSM by 11.8 percentage points over the past year.
- TG Therapeutics is more profitable, keeping 72.6 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- TG Therapeutics grew revenue faster in its latest fiscal year (+87.32% vs +65.55%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,346 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
AXSM vs TGTX FAQ
Which is bigger, Axsome Therapeutics or TG Therapeutics?
Axsome Therapeutics (AXSM) is larger, with a market capitalization of $8.82B compared with $8.48B for TG Therapeutics (TGTX).
Which stock has performed better over the past year, AXSM or TGTX?
TGTX returned +49.20% over the past 12 months, compared with +37.41% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.